Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Detrimental Nfkb1 Missense Variants Affecting the Rel-Homology Domain of P105/P50 Publisher Pubmed



Fliegauf M1, 2 ; Kinnunen M3 ; Posadascantera S1 ; Camachoordonez N1, 4 ; Abolhassani H5, 6 ; Alsina L7, 8 ; Atschekzei F9, 10 ; Bogaert DJ11, 12 ; Burns SO13, 14 ; Church JA15 ; Duckers G16 ; Freeman AF17 ; Hammarstrom L5 ; Hanitsch LG18 Show All Authors
Authors
  1. Fliegauf M1, 2
  2. Kinnunen M3
  3. Posadascantera S1
  4. Camachoordonez N1, 4
  5. Abolhassani H5, 6
  6. Alsina L7, 8
  7. Atschekzei F9, 10
  8. Bogaert DJ11, 12
  9. Burns SO13, 14
  10. Church JA15
  11. Duckers G16
  12. Freeman AF17
  13. Hammarstrom L5
  14. Hanitsch LG18
  15. Kerre T19
  16. Kobbe R20
  17. Sharapova SO21
  18. Siepermann K16
  19. Speckmann C1, 22
  20. Steiner S18
  21. Verma N13
  22. Walter JE23, 24, 25
  23. Westermannclark E23, 26
  24. Goldacker S27, 28
  25. Warnatz K27, 28
  26. Varjosalo M3, 29, 30
  27. Grimbacher B1, 2, 9, 31
Show Affiliations
Authors Affiliations
  1. 1. Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
  2. 2. CIBSS – Centre for Integrative Biological Signalling Studies, Freiburg, Germany
  3. 3. Institute of Biotechnology, University of Helsinki, Helsinki, Finland
  4. 4. Faculty of Biology, University of Freiburg, Freiburg, Germany
  5. 5. Department of Biosciences and Nutrition, NEO, Karolinska Institutet, Huddinge, Sweden
  6. 6. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, Barcelona, Spain
  8. 8. Department of Surgery and Surgical Specializations, Facultat de Medicina i Ciencies de la Salut, Barcelona, Spain
  9. 9. RESIST – Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Freiburg, Germany
  10. 10. Department for Clinical Immunology and Rheumatology, Hannover Medical School, Hanover, Germany
  11. 11. Department of Pediatrics, Division of Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
  12. 12. Primary Immunodeficiency Research Lab, Center for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, Ghent, Belgium
  13. 13. Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
  14. 14. Institute of Immunity and Transplantation, University College London, London, United Kingdom
  15. 15. Department of Pediatrics, Keck School of Medicine, University of Southern California and Children’s Hospital Los Angeles, Los Angeles, CA, United States
  16. 16. HELIOS Children’s Hospital, Krefeld, Germany
  17. 17. Laboratory of Clinical Immunology and Microbiology, National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States
  18. 18. Department of Medical Immunology, Charite – Universitatsmedizin Berlin, Berlin, Germany
  19. 19. Department of Hematology, Ghent University Hospital, Ghent, Belgium
  20. 20. Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  21. 21. Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus
  22. 22. Center for Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
  23. 23. Division of Allergy and Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
  24. 24. Division of Allergy/Immunology, Department of Pediatrics, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, United States
  25. 25. Division of Allergy and Immunology, Massachusetts General Hospital for Children, Boston, MA, United States
  26. 26. Division of Allergy and Immunology, Department of Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
  27. 27. Center for Chronic Immunodeficiency (CCI), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
  28. 28. Department of Rheumatology and Clinical Immunology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
  29. 29. Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
  30. 30. Proteomics Unit, University of Helsinki, Helsinki, Finland
  31. 31. DZIF – German Center for Infection Research, Satellite Center Freiburg, Freiburg, Germany

Source: Frontiers in Immunology Published:2022


Abstract

Most of the currently known heterozygous pathogenic NFKB1 (Nuclear factor kappa B subunit 1) variants comprise deleterious defects such as severe truncations, internal deletions, and frameshift variants. Collectively, these represent the most frequent monogenic cause of common variable immunodeficiency (CVID) identified so far. NFKB1 encodes the transcription factor precursor p105 which undergoes limited proteasomal processing of its C-terminal half to generate the mature NF-κB subunit p50. Whereas p105/p50 haploinsufficiency due to devastating genetic damages and protein loss is a well-known disease mechanism, the pathogenic significance of numerous NFKB1 missense variants still remains uncertain and/or unexplored, due to the unavailability of accurate test procedures to confirm causality. In this study we functionally characterized 47 distinct missense variants residing within the N-terminal domains, thus affecting both proteins, the p105 precursor and the processed p50. Following transient overexpression of EGFP-fused mutant p105 and p50 in HEK293T cells, we used fluorescence microscopy, Western blotting, electrophoretic mobility shift assays (EMSA), and reporter assays to analyze their effects on subcellular localization, protein stability and precursor processing, DNA binding, and on the RelA-dependent target promoter activation, respectively. We found nine missense variants to cause harmful damage with intensified protein decay, while two variants left protein stability unaffected but caused a loss of the DNA-binding activity. Seven of the analyzed single amino acid changes caused ambiguous protein defects and four variants were associated with only minor adverse effects. For 25 variants, test results were indistinguishable from those of the wildtype controls, hence, their pathogenic impact remained elusive. In summary, we show that pathogenic missense variants affecting the Rel-homology domain may cause protein-decaying defects, thus resembling the disease-mechanisms of p105/p50 haploinsufficiency or may cause DNA-binding deficiency. However, rare variants (with a population frequency of less than 0.01%) with minor abnormalities or with neutral tests should still be considered as potentially pathogenic, until suitable tests have approved them being benign. Copyright © 2022 Fliegauf, Kinnunen, Posadas-Cantera, Camacho-Ordonez, Abolhassani, Alsina, Atschekzei, Bogaert, Burns, Church, Duckers, Freeman, Hammarstrom, Hanitsch, Kerre, Kobbe, Sharapova, Siepermann, Speckmann, Steiner, Verma, Walter, Westermann-Clark, Goldacker, Warnatz, Varjosalo and Grimbacher.